[70]
Abbott concludes that Novopharm has not identified any way in which Prothonotary Milczynski either misstated the appropriate test or misapplied it. She correctly followed
Sierra Club
and, on that analysis, Novopharm failed to meet its burden. Again, this is hardly surprising given the high level of scrutiny required to be conducted by the Court and the fact that Mr. Windross did not even attest to having read the Novopharm ANDS, but merely asserted, in general, that all of the contents of any ANDS are always confidential.
Did Prothonotary Milczynski err by going beyond the evidentiary record and order that some information be included in the Protective Order?
Abbott